Skip to main content

Table 2 Risk of bias in included trials

From: A systematic review with attempted network meta-analysis of asthma therapy recommended for five to eighteen year olds in GINA steps three and four

Study ID[ref] 1
[19]
2
[20]
3
[21]
4
[22]
5
[23]
6
[24]
7
[25]
8
[26]
9
[7]
10
[9]
11
[27]
12
[28]
13
[29]
14
[30]
15
[31]
16
[8]
17
[32]
18
[33]
19
[6]
20
[34]
21
[10]
22
[35]
23
[36]
Y N ?
Sequence generation ? ? ? Y ? Y ? ? Y ? ? ? Y Y ? ? Y ? Y ? Y ? Y 9 0 14
Allocation concealment ? ? Y Y ? ? ? ? Y ? ? ? ? ? ? ? Y ? ? ? ? ? Y 5 0 18
Appropriate blinding of participants ? N Y N ? ? ? Y N Y ? ? ? ? ? ? Y ? Y ? ? N Y 6 4 13
Appropriate blinding of outcome assessors ? Y Y N ? ? ? Y ? Y ? ? ? ? ? ? ? ? ? ? ? N Y 5 2 16
Appropriate blinding of physician ? ? Y N ? ? ? Y ? Y ? ? ? ? ? ? ? ? ? ? ? N Y 4 2 17
Registration of loss to follow-up Y Y ? ? Y Y ? ? Y Y Y Y Y Y Y ? ? Y ? Y Y Y Y 16 0 7
Way missing values were dealt with ? ? ? Y ? ? ? ? Y ? ? ? ? ? ? ? Y Y ? ? ? ? ? 4 0 19
Compliance checked Y ? ? Y Y ? ? ? Y ? ? Y Y Y ? Y ? Y ? ? Y ? Y 11 0 12
Selective reporting ? ? ? ? ? N ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 0 1 22
Total times “Yes” 2 2 4 4 2 2 0 3 5 4 1 3 3 3 1 1 4 3 2 1 3 1 7    
Overall score Y/N/?                         60 9 138
  1. Each trial could score “yes” for a low, “no” for a high and “?” for an uncertain risk of bias, respectively.
  2. The 9 items are based on a combination of the Cochrane approach to assess the risk of bias, combined with the validity checklist of Jadad et al. [17, 18].